Oculus Innovative Sciences Announces Sale of 350,000 Shares

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Oculus Innovative Sciences Announces Sale of 350,000 Shares of Ruthigen Stock for $962,500 in Non-Dilutive Funding
  • Additional $4.5 million in non-dilutive funding in sale of remaining 1.65 million Ruthigen shares upon closing of Ruthigen/Pulmatrix merger expected by no later than August 2015
  • Non-dilutive funding to support growth of Oculus' new dermatology division, IntraDerm Pharmaceuticals
  • Ruthigen and Pulmatrix enter into definitive merger agreement as of March 13, 2015

PETALUMA, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ: Common Stock – OCLS, Warrants - OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the sale of 350,000 shares of Ruthigen (Nasdaq: RTGN ) stock to an undisclosed investor group at $2.75 per share for non-dilutive funding of $962,500, predicated upon the announcement of a definitive merger agreement entered into by Ruthigen and Pulmatrix, a clinical-stage biotechnology company. This merger was announced on March 13, 2015.   

If the merger closes, which is expected to occur by August 2015, Oculus has agreed to sell its remaining 1.65 million Ruthigen shares to an investor group at $2.75 per share for non-dilutive funding of approximately $4.5 million. 

Ruthigen was a wholly owned subsidiary of Oculus that was spun out as a separate company upon its initial public offering on the NASDAQ Capital Market on March 26, 2014. In this process, Ruthigen was granted a license to some of Oculus' Microcyn®-based drug assets and had been pursuing a clinical program to evaluate one such formulation for use in prevention of infection associated with abdominal surgery. As part of this licensing agreement, Oculus was to receive milestone payments and royalties. 

Following the merger and after August 31, 2016, Oculus' management anticipates one of three outcomes relative to these milestones and royalties:

1.      Ruthigen/Pulmatrix would continue to move the clinical study forward and be responsible for future milestone and royalty payments.

2.      Ruthigen/Pulmatrix would sell these licensing rights to another company, which would then be accountable to Oculus for the same milestone payments and royalties. Ruthigen/Pulmatrix has until August 31, 2016 to complete the sale or initiate the clinical program.

3.      If neither of the above alternatives are completed and/or initiated, then the drug formulations license would revert back to Oculus.

"Five and a half million dollars in non-dilutive funding will allow us to continue to grow our new dermatology division, IntraDerm Pharmaceuticals, which has already exceeded our expectations in terms of its introduction of new derm formulations for the management of atopic dermatitis and scars," said Robert Miller, Oculus' COO and CFO. "We believe these monies will move our dermatology business more quickly towards profitability without dilution to our current shareholders." 

For more information on the Ruthigen/Pulmatrix merger, visit www.ruthigen.com . For more information about Oculus' agreements with Ruthigen and Pulmatrix, please see the 8-K at http://ir.oculusis.com/sec.cfm.

About Oculus Innovative Sciences, Inc.

Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com .

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Oculus Innovative Sciences, Inc. and its subsidiaries (the "Company"). These forward-looking statements are identified by the use of words such as "expected," "continue," "anticipates," and "complete," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's common stock and warrants may be delisted from NASDAQ, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, the Company may not be able to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its annual report on Form 10-K for the year ended March 31, 2014. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Oculus®, and Microcyn® Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact: Oculus Innovative Sciences, Inc. Dan McFadden VP of Public and Investor Relations (425) 753-2105

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Pepsi Faces Georgia Labor Pressure Ahead of Strike

Updated Category News Views 121

A Pre-Dawn Labor Test Is Brewing in Georgia At 2:30 in the morning, nobody gathers outside a distribution center for the scenery. More than 100 Pepsi-Cola drivers from Atlanta and Lithonia are slated to meet Tuesday, November 24, at the Pepsi Distribution Center in Lithonia, Georgia, with Teamsters General President Sean M. O'Brien joining them. That hour matters. It puts...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 60

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 87

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Hoymiles Brings Plug-In Solar Flexibility to RE+ 2026

Updated Category News Views 105

A 1.8-kilogram box may not sound like much, but it captures where household solar is trying to go: smaller, less intimidating, and far easier to put to work. At RE+ 2026 in Las Vegas, Hoymiles laid out a residential lineup spanning plug-in solar, battery storage and conventional rooftop microinverters. This was not one flashy gadget looking for applause. It was a fairly...

Continue Reading

Top 5 Most Recently Viewed Articles

Hydreight Technologies Inc. Holds Successful Annual Meeting

Updated Category News Views 147

Successful Results from Hydreight Technologies Inc.'s Annual Meeting Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) proudly shares the positive outcomes from their recent Annual General Meeting. Conducted virtually, the meeting brought together shareholders who actively participated in decision-making. Shareholder Voting Outcomes During this significant...

Continue Reading
Discovering Leadership Themes in Anusia Gillespie's Novel

Updated Category News Views 146

Anusia Gillespie's Soul Toll: A Unique Literary Journey Soul Toll is gaining significant recognition for its imaginative storytelling which straddles the realms of ambition and awakening. This debut novel by Anusia Gillespie is becoming a staple not just in libraries, but also in yoga studios and leadership circles. Recognition from Kirkus Reviews The November issue of...

Continue Reading
First-Time Buyers' Guide to Stillwater's Housing Market

Updated Category News Views 64

The Challenge of Buying a Home in Stillwater Walking into Stillwater's housing market as a first-time buyer is like stepping onto a high-wire act. You're balancing dreams with dollars, all while the ground beneath you keeps shifting. What stands out from HelloNation's deep dive into this market, featuring Page Provence of Fisher Provence Realtors Inc., is that knowledge...

Continue Reading
Celebrating Excellence: National Catholic Reporter's 70 Awards

Updated Category News Views 127

Outstanding Achievement in Catholic Journalism The National Catholic Reporter (NCR) and its affiliated platforms, such as Global Sisters Report (GSR) and EarthBeat, have recently achieved remarkable recognition in the realm of Catholic media. With over 70 awards at the prestigious Catholic Media Awards, NCR has reaffirmed its dedication to delivering independent...

Continue Reading
Centessa Pharmaceuticals Prepares for Major Investor Events

Updated Category News Views 50

Centessa Pharmaceuticals' Upcoming Investor Conferences Centessa Pharmaceuticals plc (Nasdaq: CNTA), a pioneering clinical-stage pharmaceutical company, is set to mark its presence in several prominent investor conferences. The company's mission is to discover and develop transformative medicines aimed at enhancing patient outcomes. Guggenheim Healthcare Innovation...

Continue Reading